Skip to main content

Advertisement

SpringerLink
Log in

Vitamin D and multiple sclerosis: an update

  • Review
  • Published:
Mediterranean Journal of Nutrition and Metabolism

Abstract

Vitamin D and its biologically active metabolite, 1-alpha,25dihydroxyvitamin D3 [1,25(OH)2D3], which is produced in the dermal skin layer after exposure to ultraviolet (UV) radiation, play a central role in calcium metabolism and bone homeostasis; besides this “classical” function, they hold also other important activities, such as the regulation and differentiation of normal and tumoral cellular proliferation, and a powerful immunomodulatory activity. The relationship between vitamin D and multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system (CNS) with multifactorial pathogenesis, involves various aspects, including first of all the presence of an altered bone metabolism in subjects affected by the disease. On the basis of epidemiological data of prevalence, vitamin D and sunlight exposure may play a protective role in MS development. Nevertheless, the possible disease-modifying effect of a supplementation with vitamin D and its analogues requires further investigation, as current evidence does not support its recommendation in the specific treatment of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Holick MF (2008) Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin J Am Soc Nephrol 3(5):1548–1554

    Article  CAS  Google Scholar 

  2. Vieth R (1999) Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69(5):842–856

    CAS  Google Scholar 

  3. Alpert PT, Shaikh U (2007) The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems. Biol Res Nurs 9(2):117–129

    Article  CAS  Google Scholar 

  4. Mathieu C, Aldorini L (2009) The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 8(4):174–179

    Article  Google Scholar 

  5. Deeb KK, Trump DL, Johnson CS (2007) Vitamin D3 signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7(9):684–700

    Article  CAS  Google Scholar 

  6. Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, Zold E, Szegedi G, Brun JG, Gestelyi R, Zeher M, Bodolay E (2008) The complex role of vitamin D in autoimmune diseases. Scand J Immunol 68(3):261–269

    Article  CAS  Google Scholar 

  7. Zehnder D, Bland R, Williams MC, McNich RW, Howie AJ, Stewart PM, Hewison M (2001) Extrarenal expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase. J Clin Endocrinol Metab 86(2):888–894

    Article  CAS  Google Scholar 

  8. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005) Distribution of the vitamin D receptor and alpha-hydroxylase in human brain. J Chem Neuroanat 29(1):21–30

    Article  CAS  Google Scholar 

  9. Riaz S, Malcangio M, Miller M, Tomlinson DR (1999) A vitamin D(3) derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologia 42(11):1308–1313

    Article  CAS  Google Scholar 

  10. Kalueff AV, Eremin KO, Tuohimaa P (2004) Mechanisms of neuroprotective action of vitamin d(3). Biochemistry (Mosc) 69(7):738–741

    Article  CAS  Google Scholar 

  11. Lemire JM (1995) Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 53(1–6):599–602

    Article  CAS  Google Scholar 

  12. Penna G, Adorini L (2000) 1Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164(5):2405–2411

    CAS  Google Scholar 

  13. Adorini L (2003) Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci 987:258–261

    Article  CAS  Google Scholar 

  14. Hayes CE, Nashold FE, Spach KM, Pedersen LB (2003) The immunological functions of the vitamin D endocrine system. Cell Mol Biol (Noisy-le-grand) 49(2):277–300

    CAS  Google Scholar 

  15. Tokuda N, Levy RB (1996) 1,25-dihydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. Proc Soc Exp Biol Med 211(3):244–250

    CAS  Google Scholar 

  16. Vojinoviç S, Vojinoviç J, Cosiç V, Saviç V (2005) Effects of alfacalcidol therapy on serum cytokine levels in patients with multiple sclerosis. Srp Arh Celok Lek 133(Suppl 2):124–128 (abstract)

    Google Scholar 

  17. Shabas D, Weinreb H (2000) Preventive healthcare in women with multiple sclerosis. J Womens Health Gend Based Med 9:389–395

    Article  CAS  Google Scholar 

  18. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44(9):1687–1692

    CAS  Google Scholar 

  19. Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C, Shen V, Lindsay R (1998) Fracture history and bone loss in patients with MS. Neurology 51(4):1161–1165

    CAS  Google Scholar 

  20. Weinstock-Guttman B, Gallagher E, Baier M, Green L, Feichter J, Patrick K, Miller C, Wrest K, Ramanathan M (2004) Risk of bone loss in men with multiple sclerosis. Multiple Scler 10(2):170–175

    Article  Google Scholar 

  21. Van der Mei IA, Ponsonby AL, Blizzard L, Dwyer T (2001) Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20(3):168–174

    Article  Google Scholar 

  22. Van der Mei IA, Ponsoby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H, Kilpatrick T (2003) Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case–control study. BMJ 327(7410):316

    Article  Google Scholar 

  23. Freedman DM, Dosemeci M, Alavanja MC (2000) Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case–control study based on death certificate. Occup Environ Med 57(6):418–421

    Article  CAS  Google Scholar 

  24. Hayes CE (2000) Vitamin D: a natural inhibitor of multiple sclerosis. Proc Nutr Soc 59(4):531–535

    CAS  Google Scholar 

  25. Embry AF, Snowdon LR, Vieth R (2000) Vitamin D and seasonal fluctuation of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 48(2):271–272

    Article  CAS  Google Scholar 

  26. Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A (2005) 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Multiple Scler 11(3):266–271

    Article  CAS  Google Scholar 

  27. Menheere P, Kessels A, Damoiseaux J, Hupperts R (2008) Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14(9):1220–1224

    Article  Google Scholar 

  28. Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I (2008) A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 70(2):152–157

    Article  Google Scholar 

  29. Chaudury A (2005) Why we should offer routine supplementation of vitamin D in pregnancy and childhood to prevent multiple sclerosis. Med Hypotheses 6(3):608–618

    Article  Google Scholar 

  30. May E, Asadullah K, Zugel U (2004) Immunoregulation through 1,25-dihydroxyvitamin D3 and its analogs. Curr Drug Targets Inflamm Allergy 3(4):377–393

    Article  CAS  Google Scholar 

  31. Takeuchi A, Reddy GS, Kobayashi T, Okano T, Park J, Sharma S (1998) Nuclear factor of activated T cells (NFAT) as a molecular target for 1 alpha,25-dihydroxyvitamin D3-mediated effects. J Immunol 160(1):209–218

    CAS  Google Scholar 

  32. Cantorna MT, Woodward WD, Hayes CE, Deluca HF (1998) 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokine TGF-beta 1 and IL-4. J Immunol 160(11):5314–5319

    CAS  Google Scholar 

  33. Auer DP, Schumann EM, Kumpfel T, Gossl C, Trenkwalder C (2000) Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 47(2):276–277

    Article  CAS  Google Scholar 

  34. Embry AF, Snowdon LR, Vieth R (2000) Vitamin D and seasonal fluctuations af gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 48(2):271–272

    Article  CAS  Google Scholar 

  35. Vieth R (2006) Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr 136(4):1117–1122

    CAS  Google Scholar 

  36. Munro I (2001) Derivation of tolerable upper intake levels of nutrients. Am J Clin Nutr 74(6):865–867

    CAS  Google Scholar 

  37. Kimball SM, Ursell MR, O’Connor P, Vieth R (2007) Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr 86(3):645–651

    CAS  Google Scholar 

  38. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC (2005) A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76(9):1294–1296

    Article  CAS  Google Scholar 

  39. Fleming JO, Hummel AL, Beinlich BR (2000) Vitamin D treatment of relapsing-remitting multiple sclerosis (RRMS): a MRI-based pilot study. Neurology 54(Suppl):A338

    Google Scholar 

  40. Goldberg P, Fleming M, Picard H (1986) Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium, and vitamin D. Med Hypotheses 21(2):193–200

    Article  CAS  Google Scholar 

  41. Schwarz S, Leweling H (2005) Multiple sclerosis and nutrition. Multiple Scler 11:24–32

    Article  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurology, Hospital of Mirano, Via Mariutto 13, 30035, Mirano (VE), Italy

    Cristina Zuliani & Silvia Preto

  2. Department of Urology, Civil Hospital, Dolo (VE), Italy

    Elena Andretta

  3. Department of Neurorehabilitation, Villa Salus Hospital, Venice, Mestre, Italy

    Luciana Baroni

Authors
  1. Cristina Zuliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Preto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elena Andretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luciana Baroni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristina Zuliani.

About this article

Cite this article

Zuliani, C., Preto, S., Andretta, E. et al. Vitamin D and multiple sclerosis: an update. Mediterr J Nutr Metab 3, 115–119 (2010). https://doi.org/10.1007/s12349-010-0002-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12349-010-0002-2

Keywords

Search

Navigation